<h1>Indian transcatheter heart valve proves non-inferior in global one-year trial, supporting long-term safety and market expansion</h1> An Indian medical device manufacturer has presented one-year outcomes from a multicenter, randomized, non-inferiority trial evaluating its transcatheter heart valve (THV) system against two established international THV platforms for treatment of severe symptomatic aortic stenosis. Conducted across 31 sites in 16 countries with 768 patients, the trial reported comparable composite clinical efficacy at one year, including freedom from all-cause mortality, stroke, and procedure- or valve-related hospitalization. The study's 30-day and one-year results, published in leading peer-reviewed journals, support non-inferiority of the Indian THV. Ten-year follow-up is planned to assess long-term safety, valve durability, and echocardiographic performance, reinforcing regulatory and market positioning globally.